Ulefnersen
RNA / oligonucleotide
Evidence outlook · lead readout
FUS-ALS (NCT04768972) · Amyotrophic Lateral Sclerosis
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
FUS-ALS (NCT04768972): This trial randomized 89 participants with FUS-ALS to double-blind ulefnersen or placebo, comparing them on a composite clinical measure of functional decline, need for rescue treatment, and survival free of permanent ventilation -- a hard, disease-defining outcome rather than a lab biomarker. According to results reported outside the registry, the treatment arm showed a statistically significant benefit over placebo on this primary comparison (p=0.0005), which together with the randomized, blinded, placebo-controlled design supports a strong evidence rating.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
FUS-ALS NCT04768972 · Amyotrophic Lateral Sclerosis This trial randomized 89 participants with FUS-ALS to double-blind ulefnersen or placebo, comparing them on a composite clinical measure of functional decline, need for rescue treatment, and survival free of permanent ventilation -- a hard, disease-defining outcome rather than a lab biomarker. According to results reported outside the registry, the treatment arm showed a statistically significant benefit over placebo on this primary comparison (p=0.0005), which together with the randomized, blinded, placebo-controlled design supports a strong evidence rating. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04768972 | 3 | Change from Baseline (Day 1) through Study Day 505 in Part 1 in functional impairment (Baseline, Day 505 in Part 1) 2026-06-17 | FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005. | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Competitive landscape
This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ulefnersen: this drug | Phase 3 | RNA / oligonucleotide | FUS | Reliable signal | NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005. | |
| Edaravone (Radicava ORS) | Approved | Small molecule | Reactive oxygen species (ROS) | Weak signal | Featured results are safety only in this race | |
| Tofersen (Qalsody) | Approved | RNA / oligonucleotide | SOD1 | Partial signal | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| CB03-154 | Phase 2/3 | Small molecule | KCNQ2/3 (Kv7.2/7.3) potassium channel (opener) | not yet graded | No reviewed efficacy summary in this indication | |
| CNM-Au8 | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Ibudilast | Phase 2/3 | Small molecule | PDE4 and PDE10; macrophage migration inhibitory factor (MIF) | not yet graded | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2/3 | Small molecule | Dendritic spine density | Weak signal | Featured results are safety only in this race | |
| Dazucorilant | Phase 2 | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Foralumab | Phase 2 | Monoclonal antibody | CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-SOD | Phase 1/2 | RNA / oligonucleotide | SOD1 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent